Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$130.67 USD

130.67
1,327,706

+2.92 (2.29%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $130.73 +0.06 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day.

Zacks Equity Research

Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's

by Zacks Equity Research

FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.

Zacks Equity Research

Should iShares Morningstar MidCap Value ETF (IMCV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IMCV

Zacks Equity Research

Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device

by Zacks Equity Research

Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.

Zacks Equity Research

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $272.63 in the latest trading session, marking a -1.55% move from the prior day.

Zacks Equity Research

Biogen Inc. (BIIB) Stock Moves -0.27%: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $274.04 in the latest trading session, marking a -0.27% move from the prior day.

Zacks Equity Research

Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma

by Zacks Equity Research

Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.

Zacks Equity Research

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $286.86 in the latest trading session, marking a -0.23% move from the prior day.

Zacks Equity Research

Biogen Inc. (BIIB) Stock Moves -1.94%: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $283.44 in the latest trading session, marking a -1.94% move from the prior day.

Zacks Equity Research

Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines

by Zacks Equity Research

Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.

Zacks Equity Research

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed the most recent trading day at $285.37, moving -1.29% from the previous trading session.

Zacks Equity Research

Entrada (TRDA) Surges on Collaboration With Vertex for DMI

by Zacks Equity Research

Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.

Zacks Equity Research

BIIB vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

BIIB vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Novartis' (NVS) PNH Candidate Achieves Study Objectives

by Zacks Equity Research

Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.

Zacks Equity Research

Why Is Mirati (MRTX) Down 19.9% Since Last Earnings Report?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Esperion (ESPR) Reports Positive Data From CLEAR Study

by Zacks Equity Research

Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.

Zacks Equity Research

Is Biogen (BIIB) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage

by Zacks Equity Research

ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.

Zacks Equity Research

Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression

by Zacks Equity Research

Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.

Andrew Rocco headshot

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

by Andrew Rocco

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

Zacks Equity Research

Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe

by Zacks Equity Research

Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.

Zacks Equity Research

Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

by Zacks Equity Research

Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.

Zacks Equity Research

Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal

by Kinjel Shah

Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.

Zacks Equity Research

Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.